Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07737925
What this trial is testing

LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan

Who this might be right for
Prostate CancerMetastatic Castrate Resistant Prostate Cancer
Thomas Jefferson University 30
Testing effectiveness (Phase 2)Study completedNCT03098836
What this trial is testing

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Daniel George, MD 93
Not applicableUnknownNCT04507698
What this trial is testing

INTERVAL - Intense Exercise Trial for Men With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Guy's and St Thomas' NHS Foundation Trust 80
Testing effectiveness (Phase 2)Ended earlyNCT02146833
What this trial is testing

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

Who this might be right for
Prostate Cancer
Karyopharm Therapeutics Inc 20
Testing effectiveness (Phase 2)UnknownNCT06001255
What this trial is testing

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

Who this might be right for
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Hansoh BioMedical R&D Company 120
Testing effectiveness (Phase 2)WithdrawnNCT03709550
What this trial is testing

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma in the Soft Tissue+6 more
Roswell Park Cancer Institute
Large-scale testing (Phase 3)Looking for participantsNCT06629779
What this trial is testing

Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Pfizer 900
Testing effectiveness (Phase 2)Looking for participantsNCT06785636
What this trial is testing

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Who this might be right for
mCRPC (Metastatic Castration-resistant Prostate Cancer)Prostate Cancer
Pathos AI, Inc. 120
Post-approval studies (Phase 4)Active Not RecruitingNCT04597125
What this trial is testing

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Bayer 654
Testing effectiveness (Phase 2)Study completedNCT01549951
What this trial is testing

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Millennium Pharmaceuticals, Inc. 50
Testing effectiveness (Phase 2)Looking for participantsNCT07206056
What this trial is testing

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Who this might be right for
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals 188
Early research (Phase 1)Study completedNCT01692262
What this trial is testing

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),Efficacy,Safety and Tolerability,+3 more
AstraZeneca 59
Not applicableStudy completedNCT04281147
What this trial is testing

Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body

Who this might be right for
Prostate Cancer
Bayer 4,301
Early research (Phase 1)Looking for participantsNCT04729114
What this trial is testing

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration Resistant Prostate CancerMetastatic Castration-sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 174
Early research (Phase 1)Looking for participantsNCT03460977
What this trial is testing

Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer (SCLC)Follicular Lymphoma (FL)
Pfizer 453
Early research (Phase 1)Study completedNCT02705469
What this trial is testing

ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics 44
Early research (Phase 1)Active Not RecruitingNCT06046040
What this trial is testing

TmPSMA-02 in mCRPC

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
University of Pennsylvania 30
Testing effectiveness (Phase 2)Temporarily pausedNCT04071236
What this trial is testing

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Who this might be right for
Metastatic Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+1 more
National Cancer Institute (NCI) 90
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05570994
What this trial is testing

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Who this might be right for
Metastatic Castration-resistant Prostate CancerProstate Cancer MetastaticCastrate Resistant Prostate Cancer
British Columbia Cancer Agency 50
Large-scale testing (Phase 3)Study completedNCT03761225
What this trial is testing

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer
AB Science 714
Next Page